JMP Securities reaffirmed their market outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a $7.00 price target on the stock.
ELEV has been the subject of several other reports. HC Wainwright restated a buy rating and set a $6.00 price objective on shares of Elevation Oncology in a research report on Tuesday, April 9th. Wedbush restated an outperform rating and set a $8.00 price objective on shares of Elevation Oncology in a research report on Friday, May 3rd. Stephens assumed coverage on Elevation Oncology in a research report on Tuesday, May 14th. They issued an overweight rating and a $8.00 target price for the company. Finally, Piper Sandler assumed coverage on Elevation Oncology in a research report on Friday, May 31st. They issued an overweight rating and a $10.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of Buy and a consensus price target of $7.80.
Check Out Our Latest Analysis on Elevation Oncology
Elevation Oncology Price Performance
Elevation Oncology (NASDAQ:ELEV – Get Free Report) last announced its quarterly earnings data on Thursday, May 2nd. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02). On average, sell-side analysts forecast that Elevation Oncology will post -0.92 EPS for the current fiscal year.
Hedge Funds Weigh In On Elevation Oncology
Several large investors have recently bought and sold shares of ELEV. SG Americas Securities LLC bought a new position in shares of Elevation Oncology during the first quarter worth about $63,000. Vanguard Group Inc. raised its position in shares of Elevation Oncology by 30.8% during the first quarter. Vanguard Group Inc. now owns 1,532,045 shares of the company’s stock worth $7,859,000 after acquiring an additional 360,799 shares during the last quarter. Affinity Asset Advisors LLC bought a new position in shares of Elevation Oncology during the first quarter worth about $6,509,000. Darwin Global Management Ltd. bought a new position in shares of Elevation Oncology during the first quarter worth about $11,968,000. Finally, Artal Group S.A. bought a new position in shares of Elevation Oncology during the first quarter worth about $7,762,000. 83.70% of the stock is currently owned by institutional investors.
Elevation Oncology Company Profile
Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Featured Stories
- Five stocks we like better than Elevation Oncology
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Real Estate Stock Signals a Boom in Manufacturing Activity
- How to Invest in Biotech Stocks
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- Why Understanding Call Option Volume is Essential to Successful Options Trading
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.